

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

NCT05184088

Status	RECRUITING
Phase	Phase 3
Sponsor	Life Molecular Imaging GmbH
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (16)

- Males and females age ≥18 years
- Able to understand, sign and date written informed consent
- Written informed consent must be obtained before any study procedures are performed
- Subjects being considered for a possible diagnosis of cardiac amyloidosis by
- \. One of the following conditions:

... and 11 more (see full listing online)

Exclusion (6)

- Any known allergic reactions or hypersensitivity towards any compound of the study drug
- Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN)
- Inability to lay flat for up to 60 min
- Pregnant, lactating or breastfeeding
- Unwilling and/or unable to cooperate with study procedures

... and 1 more (see full listing online)

Locations (14 total)

St Luke's Hospital, Kansas City, Kansas, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
... and 11 more locations